Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3481]

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Temab-A plus bevacizumab shows promising response rates in advanced colorectal...

Dr Michael Cecchini - Yale School of Medicine, New Haven, USA

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer ( Dr Michael Cecchini - Yale School of Medicine, New Haven, USA )

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth

ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

PRAME-targeted TCR therapy shows high response rates in metastatic uveal...

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )

ESMO 2025: Latest in mRCC

Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor...

ESMO 2025: Latest in mRCC ( Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor Grünwald )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer ( Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA )

Visugromab plus nivolumab significantly increases pathologic response in muscle...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

ESMO 2025: Latest in EGFR mutant NSCLC

Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini

ESMO 2025: Latest in EGFR mutant NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini )

More from ecancer